RED TERAV - Investigadores

Investigadores

Institut Català d’Oncologia ICO (IDIBELL)

Inmunoterapia Celular (células CAR)

Investigadores
Publicaciones

Ana Maria Sureda Balari

Investigador principal

Grupo de Investigación: Institut Català d’Oncologia ICO (IDIBELL)

Ramon Alemany Bonastre

Investigador principal

Grupo de Investigación: Institut Català d’Oncologia ICO (IDIBELL)

Cristina Fillat Fonts

Investigador colaborador

Grupo de Investigación: Institut Català d’Oncologia ICO (IDIBELL)

Otero-Mateo M., Estrany F., Arcas-Márquez S., Moya-Borrego L., Castellano G., Castany M., Alemany R., Fillat C.. KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysis. Molecular Therapy Oncology. 20 March 2025. DOI: 10.1016/j.omton.2024.200928.

Bachiller M., Barceló-Genestar N., Rodriguez-Garcia A., Alserawan L., Dobaño-López C., Giménez-Alejandre M., Castellsagué J., Colell S., Otero-Mateo M., Antoñana-Vildosola A., Español-Rego M., Ferruz N., Pascal M., Martín-Antonio B., Anguela X.M., Fillat C., Olesti E., Calvo G., Juan M., Delgado J., Pérez-Galán P., Urbano-Ispizua Á., Guedan S.. ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma. Molecular Therapy. 8 January 2025. DOI: 10.1016/j.ymthe.2024.11.028.

Impacto: 12.1. Cuartil: Q1 (1er decil)

Xu C., Pascual-Sabater S., Fillat C., Goel A.. The LAMB3-EGFR signaling pathway mediates synergistic Anti-Cancer effects of berberine and emodin in Pancreatic cancer. Biochemical Pharmacology. October 2024. DOI: 10.1016/j.bcp.2024.116509.

Impacto: 5.3. Cuartil: Q1

Morales-Molina A., Rodriguez-Milla M.A., Garcia-Rodriguez P., Hidalgo L., Alemany R., Garcia-Castro J.. Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapy. Molecular Therapy Oncology. 19 September 2024. DOI: 10.1016/j.omton.2024.200863.

Mateu-Bosch A., Segur-Bailach E., Muñoz-Moreno E., Barallobre M.J., Arbonés M.L., Gea-Sorlí S., Tort F., Ribes A., García-Villoria J., Fillat C.. Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model. Molecular Therapy Methods and Clinical Development. 12 September 2024. DOI: 10.1016/j.omtm.2024.101276.

Li Y., Xu C., Han H., Pascual-Sabater S., Fillat C., Goel A.. Aronia Berry Extract Modulates MYD88/NF-kB/P-Glycoprotein Axis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Pharmaceuticals. July 2024. DOI: 10.3390/ph17070911.

Impacto: 4.3. Cuartil: Q1

Martin-Liberal J., Garralda E., García-Donas J., Soto-Castillo J.J., Mussetti A., Codony C., Martin-Lluesma S., Muñoz S., Galvao V., Lostes J., Rotxes M., Prat-Vidal C., Palomero J., Muñoz A., Moreno R., García del Muro X., Sureda A., Alemany R., Gros A., Piulats J.M.. Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study. Future Oncology. 2024. DOI: 10.1080/14796694.2024.2385287.

Impacto: 3.0. Cuartil: Q2

Costa-Garcia M., Rojas J., Ramos M., Barlabé P., Calvo P., Navas J., Alemany R., Moreno R.. Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors. Cancer Immunology, Immunotherapy. January 2024. DOI: 10.1007/s00262-023-03611-3.

Impacto: 4.6. Cuartil: Q1

Mateu-Bosch A., Segur-Bailach E., García-Villoria J., Gea-Sorlí S., Ruiz I., del Rey J., Camps J., Guitart-Mampel M., Garrabou G., Tort F., Ribes A., Fillat C.. Modeling Glutaric Aciduria Type I in human neuroblastoma cells recapitulates neuronal damage that can be rescued by gene replacement. Gene Therapy. January 2024. DOI: 10.1038/s41434-023-00428-8.

Impacto: 4.6. Cuartil: Q1

Wenthe J., Eriksson E., Hellström A.C., Moreno R., Ullenhag G., Alemany R., Lövgren T., Loskog A.. Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. Journal of Translational Medicine. December 2023. DOI: 10.1186/s12967-023-04374-2.

Impacto: 6.1. Cuartil: Q1

Soto-Castillo J.J., Llavata-Marti L., Fort-Culillas R., Andreu-Cobo P., Moreno R., Codony C., García del Muro X., Alemany R., Piulats J.M., Martin-Liberal J.. SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy. International Journal of Molecular Sciences. July 2023. DOI: 10.3390/ijms241311143.

Impacto: 4.9. Cuartil: Q1

Okuno K., Xu C., Pascual-Sabater S., Tokunaga M., Takayama T., Han H., Fillat C., Kinugasa Y., Goel A.. Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Biomedicines. January 2023. DOI: 10.3390/biomedicines11010119.

Impacto: 3.9. Cuartil: Q1

Garofalo M., Wieczorek M., Anders I., Staniszewska M., Lazniewski M., Prygiel M., Zasada A.A., Szczepińska T., Plewczynski D., Salmaso S., Caliceti P., Cerullo V., Alemany R., Rinner B., Pancer K., Kuryk L.. Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model. Frontiers in Oncology. 2023. DOI: 10.3389/fonc.2023.1259314.

Impacto: 3.5. Cuartil: Q2

Ausania F., Gonzalez-Abós C., Martinez-Perez A., Arrocha C., Pineda-Garcés C., Landi F., Fillat C., Garcia-Valdecasas J.C.. Postoperative day one systemic inflammatory response syndrome is a powerful early biomarker of clinically relevant pancreatic fistula. HPB. January 2023. DOI: 10.1016/j.hpb.2022.08.016.

Impacto: 2.7. Cuartil: Q1

García-Mulero S., Fornelino R., Punta M., Lise S., Varela M., del Carpio L.P., Moreno R., Costa-García M., Rieder D., Trajanoski Z., Gros A., Alemany R., Piulats J.M., Sanz-Pamplona R.. Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients. OncoImmunology. 2023. DOI: 10.1080/2162402X.2023.2261278.

Impacto: 6.5. Cuartil: Q1

Cloquell A., Mateo I., Gambera S., Pumarola M., Alemany R., García-Castro J., Perisé-Barrios A.J.. Systemic cellular viroimmunotherapy for canine high-grade gliomas. Journal for ImmunoTherapy of Cancer. 20 December 2022. DOI: 10.1136/jitc-2022-005669.

Farguell J., Holguin V., González C., Gil I., Arrocha C., Landi F., Vaquero E., Gines A., Fillat C., Ausania F.. Telemedicine and intraductal papillary mucinous neoplasms: Analysis of a new follow-up strategy during COVID-19 outbreak. Surgery (United States). December 2022. DOI: 10.1016/j.surg.2022.09.005.

Impacto: 3.8. Cuartil: Q1

Okuno K., Xu C., Pascual-Sabater S., Tokunaga M., Han H., Fillat C., Kinugasa Y., Goel A.. Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals. October 2022. DOI: 10.3390/ph15101199.

Duch P., Díaz-Valdivia N., Ikemori R., Gabasa M., Radisky E.S., Arshakyan M., Gea-Sorlí S., Mateu-Bosch A., Bragado P., Carrasco J.L., Mori H., Ramírez J., Teixidó C., Reguart N., Fillat C., Radisky D.C., Alcaraz J.. Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma. Matrix Biology. August 2022. DOI: 10.1016/j.matbio.2022.06.009.

Impacto: 6.9. Cuartil: Q1

Luque J., Mendes I., Gómez B., Morte B., López de Heredia M., Herreras E., Corrochano V., Bueren J., Gallano P., Artuch R., Fillat C., Pérez-Jurado L.A., Montoliu L., Carracedo Á., Millán J.M., Webb S.M., Palau F., Aguado C., Aguado C., Aguilera P., Albiñana V., Alías L., Almoguera B., Alonso J., Alonso-Ferreira V., Alvarez-Mora M.I., Antiñolo G., Arbones M.L., Arenas J., Arjona E., Armangue T., Armstrong J., Arnedo M., Masó A.A., Avila-Fernandez A., Ayuso C., Badell I., Badenas C., Baeza M.L., Baiget M., Balcells S., Ballesta-Martínez M.J., Barahona M.J., Barros F., Bartoccioni P.C., Pilar Bayona-Bafaluy M., Benito Sanz S., Bernabéu C., Bernal S., Blanco-Kelly F., Blázquez A., Bodoy S., Bogliolo M., Borralleras C., Borrego S., Botella L.M., Bou de Pieri F., Bovolenta P., Bravo-Gil N., Brea A., Bueno-Lozano G., Bueren J., Bustamante A., Caballero T., Camacho-Macorra C., Cámara Y., Camats-Tarruella N., Campos Barros Á., Campuzano V., Cantarero L., Cantó J., Caparrós-Martín J., Cardellach F., Carmona R., Carrera C., Carretero M., Casado M., Casado J., Casasnovas C., Cascón A., Casino P., Castaño L., Castilla-Vallmanya L., Catala A., Luisa Cayuela M., Cediel R., Cervera J., Codina-Solà M., Contreras J., Cormand B., Corominas R., Corral J., Cortés-Rodríguez A., Corton M., Costa-Roger M., Cozar M., Crespo I., Crispi F.. CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative. Clinical Genetics. 01 May-June 2022. DOI: 10.1111/cge.14113.

Impacto: 3.5. Cuartil: Q2

Garcia-Carbonero R., Bazan-Peregrino M., Gil-Martín M., Álvarez R., Macarulla T., Riesco-Martinez M.C., Verdaguer H., Guillén-Ponce C., Farrera-Sal M., Moreno R., Mato-Berciano A., Maliandi M.V., Torres-Manjon S., Costa M., Del Pozo N., Martínez De Villarreal J., Real F.X., Vidal N., Capella G., Alemany R., Blasi E., Blasco C., Cascalló M., Salazar R.. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 25 March 2022. DOI: 10.1136/jitc-2021-003255.

Wenthe J., Naseri S., Hellström A.C., Moreno R., Ullenhag G., Alemany R., Lövgren T., Eriksson E., Loskog A.. Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition. Molecular Therapy Oncolytics. 17 March 2022. DOI: 10.1016/j.omto.2022.01.003.

Impacto: 5.7. Cuartil: Q2

Pascual-Sabater S., Raimondi G., Mato-Berciano A., Vaquero E.C., Ausania F., Fillat C.. Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids. STAR Protocols. 17 December 2021. DOI: 10.1016/j.xpro.2021.101017.

Wert-Carvajal C., Sánchez-García R., Macías J.R., Sanz-Pamplona R., Pérez A.M., Alemany R., Veiga E., Sorzano C.Ó.S., Muñoz-Barrutia A.. Predicting MHC I restricted T cell epitopes in mice with NAP-CNB, a novel online tool. Scientific Reports. December 2021. DOI: 10.1038/s41598-021-89927-5.

Impacto: 4.996. Cuartil: Q2

Bazan-Peregrino M., Garcia-Carbonero R., Laquente B., Álvarez R., Mato-Berciano A., Gimenez-Alejandre M., Morgado S., Rodríguez-García A., Maliandi M.V., Riesco M.C., Moreno R., Ginestà M.M., Perez-Carreras M., Gornals J.B., Prados S., Perea S., Capella G., Alemany R., Salazar R., Blasi E., Blasco C., Cascallo M., Hidalgo M.. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. Journal for ImmunoTherapy of Cancer. 9 November 2021. DOI: 10.1136/jitc-2021-003254.

Impacto: 12.469. Cuartil: Q1 (1er decil)

Farrera-Sal M., Moreno R., Mato-Berciano A., Maliandi M.V., Bazan-Peregrino M., Alemany R.. Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation. Molecular Therapy Oncolytics. 24 September 2021. DOI: 10.1016/j.omto.2021.05.009.

Impacto: 6.311. Cuartil: Q2

Raimondi G., Gea-Sorlí S., Otero-Mateo M., Fillat C.. Inhibition of mir-222 by oncolytic adenovirus-encoded mirna sponges promotes viral oncolysis and elicits antitumor effects in pancreatic cancer models. Cancers. 1 July 2021. DOI: 10.3390/cancers13133233.

Impacto: 6.575. Cuartil: Q1

Núñez-Manchón E., Farrera-Sal M., Otero-Mateo M., Castellano G., Moreno R., Medel D., Alemany R., Villanueva E., Fillat C.. Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses. NAR Cancer. 1 June 2021. DOI: 10.1093/narcan/zcab015.

Farrera-Sal M., Moya-Borrego L., Bazan-Peregrino M., Alemany R.. Evolving status of clinical immunotherapy with oncolytic adenovirus. Clinical Cancer Research. 1 June 2021. DOI: 10.1158/1078-0432.CCR-20-1565.

Impacto: 13.801. Cuartil: Q1 (1er decil)

Mato-Berciano A., Morgado S., Maliandi M.V., Farrera-Sal M., Gimenez-Alejandre M., Ginestà M.M., Moreno R., Torres-Manjon S., Moreno P., Arias-Badia M., Rojas L.A., Capellà G., Alemany R., Cascallo M., Bazan-Peregrino M.. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11. Journal of Controlled Release. 10 April 2021. DOI: 10.1016/j.jconrel.2021.02.035.

Impacto: 11.467. Cuartil: Q1 (1er decil)

Giménez-Roig J., Núñez-Manchón E., Alemany R., Villanueva E., Fillat C.. Codon Usage and Adenovirus Fitness: Implications for Vaccine Development. Frontiers in Microbiology. 10 February 2021. DOI: 10.3389/fmicb.2021.633946.

Impacto: 6.064. Cuartil: Q1

Kiyokawa J., Kawamura Y., Ghouse S.M., Acar S., Barçın E., Martínez-Quintanilla J., Martuza R.L., Alemany R., Rabkin S.D., Shah K., Wakimoto H.. Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma. Clinical Cancer Research. 1 February 2021. DOI: 10.1158/1078-0432.CCR-20-2400.

Impacto: 13.801. Cuartil: Q1 (1er decil)

Acosta J., Pérez E., Sánchez‐murcia P.A., Fillat C., Fernández‐lucas J.. Molecular basis of ndt‐mediated activation of nucleoside‐ based prodrugs and application in suicide gene therapy. Biomolecules. January 2021. DOI: 10.3390/biom11010120.

Impacto: 6.064. Cuartil: Q2

Murillo-Cuesta S., Artuch R., Asensio F., de la Villa P., Dierssen M., Enríquez J.A., Fillat C., Fourcade S., Ibáñez B., Montoliu L., Oliver E., Pujol A., Salido E., Vallejo M., Varela-Nieto I.. The Value of Mouse Models of Rare Diseases: A Spanish Experience. Frontiers in Genetics. 14 October 2020. DOI: 10.3389/fgene.2020.583932.

Impacto: 4.599. Cuartil: Q2

Boni J., Rubio-Perez C., López-Bigas N., Fillat C., de la Luna S.. The DYRK family of kinases in cancer: Molecular functions and therapeutic opportunities. Cancers. August 2020. DOI: 10.3390/cancers12082106.

Impacto: 6.639. Cuartil: Q1

Farrera-Sal M., de Sostoa J., Nuñez-Manchón E., Moreno R., Fillat C., Bazan-Peregrino M., Alemany R.. Arming oncolytic adenoviruses: Effect of insertion site and splice acceptor on transgene expression and viral fitness. International Journal of Molecular Sciences. July 2020. DOI: 10.3390/ijms21145158.

Impacto: 5.923. Cuartil: Q1

Bonjoch L., Franch-Expósito S., Garre P., Belhadj S., Muñoz J., Arnau-Collell C., Díaz-Gay M., Gratacós-Mulleras A., Raimondi G., Esteban-Jurado C., Soares de Lima Y., Herrera-Pariente C., Cuatrecasas M., Ocaña T., Castells A., Fillat C., Capellá G., Balaguer F., Caldés T., Valle L., Castellví-Bel S.. Germline Mutations in FAF1 Are Associated With Hereditary Colorectal Cancer. Gastroenterology. July 2020. DOI: 10.1053/j.gastro.2020.03.015.

Impacto: 22.682. Cuartil: Q1 (1er decil)

Raimondi G., Mato-Berciano A., Pascual-Sabater S., Rovira-Rigau M., Cuatrecasas M., Fondevila C., Sánchez-Cabús S., Begthel H., Boj S.F., Clevers H., Fillat C.. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. EBioMedicine. June 2020. DOI: 10.1016/j.ebiom.2020.102786.

Impacto: 8.143. Cuartil: Q1

Sendra L., Miguel A., Navarro-Plaza M.C., Herrero M.J., de la Higuera J., Cháfer-Pericás C., Aznar E., Marcos M.D., Martínez-Máñez R., Rojas L.A., Alemany R., Aliño S.F.. Gold nanoparticle-assisted virus formation by means of the delivery of an oncolytic adenovirus genome. Nanomaterials. June 2020. DOI: 10.3390/nano10061183.

Impacto: 5.076. Cuartil: Q1

Barlabé P., Sostoa J.d., Fajardo C.A., Alemany R., Moreno R.. Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers. Cancer Gene Therapy. 1 May 2020. DOI: 10.1038/s41417-019-0110-1.

Impacto: 5.987. Cuartil: Q1

Vila-Navarro E., Fernandez-Castañer E., Rovira-Rigau M., Raimondi G., Vila-Casadesus M., Lozano J.J., Soubeyran P., Iovanna J., Castells A., Fillat C., Gironella M.. MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics. Oncogenesis. 1 May 2020. DOI: 10.1038/s41389-020-0227-y.

Impacto: 7.485. Cuartil: Q1

Ruano D., López-Martín J.A., Moreno L., Lassaletta Á., Bautista F., Andión M., Hernández C., González-Murillo Á., Melen G., Alemany R., Madero L., García-Castro J., Ramírez M.. First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors. Molecular Therapy. 8 April 2020. DOI: 10.1016/j.ymthe.2020.01.019.

Impacto: 11.454. Cuartil: Q1 (1er decil)

Farrera-Sal M., Fillat C., Alemany R.. Effect of transgene location, transcriptional control elements and transgene features in armed oncolytic adenoviruses. Cancers. April 2020. DOI: 10.3390/cancers12041034.

Impacto: 6.639. Cuartil: Q1

Ikemori R., Gabasa M., Duch P., Vizoso M., Bragado P., Arshakyan M., Luis I.C., Marín A., Moran S., Castro M., Fuster G., Gea-Sorli S., Jauset T., Soucek L., Montuenga L.M., Esteller M., Monso E., Peinado V.I., Gascon P., Fillat C., Hilberg F., Reguart N., Alcaraz J.. Epigenetic SmAd3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma. Cancer Research. 15 January 2020. DOI: 10.1158/0008-5472.CAN-19-0637.

Impacto: 12.701. Cuartil: Q1 (1er decil)

Brugada-Vilà P., Cascante A., Lázaro M.Á., Castells-Sala C., Fornaguera C., Rovira-Rigau M., Albertazzi L., Borros S., Fillat C.. Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses. Theranostics. 2020. DOI: 10.7150/thno.40902.

Impacto: 11.556. Cuartil: Q1 (1er decil)

Garcia-Moure M., Martinez-Velez N., Gonzalez-Huarriz M., Marrodán L., Cascallo M., Alemany R., Patiño-García A., Alonso M.M.. The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models. Scientific Reports. 1 December 2019. DOI: 10.1038/s41598-019-51014-1.

Impacto: 3.998. Cuartil: Q1

Tort F., Ugarteburu O., Texidó L., Gea-Sorlí S., García-Villoria J., Ferrer-Cortès X., Arias Á., Matalonga L., Gort L., Ferrer I., Guitart-Mampel M., Garrabou G., Vaz F.M., Pristoupilova A., Rodríguez M.I.E., Beltran S., Cardellach F., Wanders R.J.A., Fillat C., García-Silva M.T., Ribes A.. Mutations in TIMM50 cause severe mitochondrial dysfunction by targeting key aspects of mitochondrial physiology. Human Mutation. 1 October 2019. DOI: 10.1002/humu.23779.

Impacto: 4.124. Cuartil: Q2

Luna J., Boni J., Cuatrecasas M., Bofill-De Ros X., Núñez-Manchón E., Gironella M., Vaquero E.C., Arbones M.L., De La Luna S., Fillat C.. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut. 1 August 2019. DOI: 10.1136/gutjnl-2018-316128.

Impacto: 19.819. Cuartil: Q1 (1er decil)

García M., Moreno R., Gil-Martin M., Cascallò M., De Olza M.O., Cuadra C., Piulats J.M., Navarro V., Domenech M., Alemany R., Salazar R.. A Phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Human Gene Therapy. March 2019. DOI: 10.1089/hum.2018.107.

Impacto: 4.51. Cuartil: Q1

Eriksson E., Milenova I., Wenthe J., Moreno R., Alemany R., Loskog A.. IL-6 signaling blockade during CD40-mediated immune activation favors antitumor factors by reducing TGF-b, collagen type I, and PD-L1/PD-1. Journal of Immunology. 1 February 2019. DOI: 10.4049/jimmunol.1800717.

Impacto: 4.886. Cuartil: Q2

De Sostoa J., Fajardo C.A., Moreno R., Ramos M.D., Farrera-Sal M., Alemany R.. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. Journal for ImmunoTherapy of Cancer. 25 January 2019. DOI: 10.1186/s40425-019-0505-4.

Impacto: 10.252. Cuartil: Q1 (1er decil)

Pascual-Pasto G., Bazan-Peregrino M., Olaciregui N.G., Restrepo-Perdomo C.A., Mato-Berciano A., Ottaviani D., Weber K., Correa G., Paco S., Vila-Ubach M., Cuadrado-Vilanova M., Castillo-Ecija H., Botteri G., Garcia-Gerique L., Moreno-Gilabert H., Gimenez-Alejandre M., Alonso-Lopez P., Farrera-Sal M., Torres-Manjon S., Ramos-Lozano D., Moreno R., Aerts I., Doz F., Cassoux N., Chapeaublanc E., Torrebadell M., Roldan M., König A., Suñol M., Claverol J., Lavarino C., De Torres C., Fu L., Radvanyi F., Munier F.L., Catalá-Mora J., Mora J., Alemany R., Cascalló M., Chantada G.L., Carcaboso A.M.. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Science Translational Medicine. 23 January 2019. DOI: 10.1126/scitranslmed.aat9321.

Impacto: 16.304. Cuartil: Q1 (1er decil)

Rovira-Rigau M., Raimondi G., Marín M.Á., Gironella M., Alemany R., Fillat C.. Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer. Molecular Therapy. 2 January 2019. DOI: 10.1016/j.ymthe.2018.09.016.

Impacto: 8.986. Cuartil: Q1 (1er decil)

Moreno R., Fajardo C., Farrera-Sal M., Perise-Barrios A., Morales-Molina A., Al-Zaher A., García-Castro J., Alemany R.. Enhanced antitumor efficacy of oncolytic adenovirus–loaded menstrual blood–derived mesenchymal stem cells in combination with peripheral blood mononuclear cells. Molecular Cancer Therapeutics. January 2019. DOI: 10.1158/1535-7163.MCT-18-0431.

Impacto: 5.615. Cuartil: Q1

Guedan S., Alemany R.. CAR-T cells and oncolytic viruses: Joining forces to overcome the solid tumor challenge. Frontiers in Immunology. 23 October 2018. DOI: 10.3389/fimmu.2018.02460.

Impacto: 4.716. Cuartil: Q2

Kuryk L., Møller A., Garofalo M., Cerullo V., Pesonen S., Alemany R., Jaderberg M.. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. Journal of Medical Virology. October 2018. DOI: 10.1002/jmv.25229.

Impacto: 2.049. Cuartil: Q3

Cejalvo T., Perise-Barrios A.J., del Portillo I., Laborda E., Rodriguez-Milla M.A., Cubillo I., Vazquez F., Sardon D., Ramirez M., Alemany R., del Castillo N., García-Castro J.. Remission of spontaneous canine tumors after systemic cellular viroimmunotherapy. Cancer Research. 1 September 2018. DOI: 10.1158/0008-5472.CAN-17-3754.

Impacto: 8.378. Cuartil: Q1 (1er decil)

Fillat C., Del Río M., Martínez-Santamaría L., Bueren J.A.. Advanced therapies for rare diseases. Arbor. July-September 2018. DOI: 10.3989/arbor.2018.789n3009.

Sangrador I., Molero X., Campbell F., Franch-Exposito S., Rovira-Rigau M., Samper E., Domínguez-Fraile M., Fillat C., Castells A., Vaquero E.C.. Zeb1 in stromal myofibroblasts promotes kras-driven development of pancreatic cancer. Cancer Research. 15 May 2018. DOI: 10.1158/0008-5472.CAN-17-1882.

Impacto: 8.378. Cuartil: Q1 (1er decil)

Rozen E.J., Roewenstrunk J., Barallobre M.J., Di Vona C., Jung C., Figueiredo A.F., Luna J., Fillat C., Arbonés M.L., Graupera M., Valverde M.A., de la Luna S.. DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells. Cell Reports. 8 May 2018. DOI: 10.1016/j.celrep.2018.04.008.

Impacto: 7.815. Cuartil: Q1

Wing A., Fajardo C.A., Posey A.D., Shaw C., Da T., Young R.M., Alemany R., June C.H., Guedan S.. Improving CART-cell therapy of solid tumors with oncolytic virus–driven production of a bispecific T-cell engager. Cancer Immunology Research. May 2018. DOI: 10.1158/2326-6066.CIR-17-0314.

Impacto: 8.619. Cuartil: Q1 (1er decil)

Al-Zaher A.A., Moreno R., Fajardo C.A., Arias-Badia M., Farrera M., de Sostoa J., Rojas L.A., Alemany R.. Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus. Molecular Therapy Oncolytics. 30 March 2018. DOI: 10.1016/j.omto.2018.01.003.

Impacto: 5.71. Cuartil: Q1

Vila-Casadesús M., Vila-Navarro E., Raimondi G., Fillat C., Castells A., Lozano J.J., Gironella M.. Deciphering microRNA targets in pancreatic cancer using miRComb R package. Oncotarget. 2018. DOI: 10.18632/oncotarget.24034.

Rodríguez-Comas J., Moreno-Asso A., Moreno-Vedia J., Martín M., Castaño C., Marzà-Florensa A., Bofill-De Ros X., Mir-Coll J., Montané J., Fillat C., Gasa R., Novials A., Servitja J.M.. Stress-induced microrna-708 impairs b-cell function and growth. Diabetes. 1 December 2017. DOI: 10.2337/db16-1569.

Impacto: 7.273. Cuartil: Q1 (1er decil)

Eriksson E., Milenova I., Wenthe J., Hle M.S., Leja-Jarblad J., Ullenhag G., Dimberg A., Moreno R., Alemany R., Loskog A.. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clinical Cancer Research. 1 October 2017. DOI: 10.1158/1078-0432.CCR-17-0285.

Impacto: 10.199. Cuartil: Q1 (1er decil)

Ros X.B.D., Rovira-Rigau M., Fillat C.. Implications of MicroRNAs in oncolytic virotherapy. Frontiers in Oncology. 4 July 2017. DOI: 10.3389/fonc.2017.00142.

Impacto: 4.416. Cuartil: Q2

Fajardo C., Guedan S., Rojas L., Moreno R., Arias-Badia M., De Sostoa J., June C., Alemany R.. Oncolytic adenoviral delivery of an EGFR-targeting t-cell engager improves antitumor efficacy. Cancer Research. 15 April 2017. DOI: 10.1158/0008-5472.CAN-16-1708.

Impacto: 9.13. Cuartil: Q1 (1er decil)

Villanueva E., Navarro P., Rovira-Rigau M., Sibilio A., Méndez R., Fillat C.. Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies. Nature Communications. 16 March 2017. DOI: 10.1038/ncomms14833.

Impacto: 12.353. Cuartil: Q1 (1er decil)

Eriksson E., Moreno R., Milenova I., Liljenfeldt L., Dieterich L.C., Christiansson L., Karlsson H., Ullenhag G., Mangsbo S.M., Dimberg A., Alemany R., Loskog A.. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment. Gene Therapy. 1 February 2017. DOI: 10.1038/gt.2016.80.

Impacto: 3.203. Cuartil: Q2

Moreno R., Rojas L.A., Villellas F.V., Soriano V.C., Garciá-Castro J., Fajardo C.A., Alemany R.. Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus. Stem Cells International. 2017. DOI: 10.1155/2017/3615729.

Rincón E., Cejalvo T., Kanojia D., Alfranca A., Rodríguez-Milla M.Á., Hoyos R.A.G., Han Y., Zhang L., Alemany R., Lesniak M.S., García-Castro J.. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. Oncotarget. 2017. DOI: 10.18632/oncotarget.17557.

Mato-Berciano A., Raimondi G., Maliandi M.V., Alemany R., Montoliu L., Fillat C.. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel. Oncotarget. 2017. DOI: 10.18632/oncotarget.15169.

Rojas L.A., Moreno R., Calderón H., Alemany R.. Adenovirus coxsackie adenovirus receptor-mediated binding to human erythrocytes does not preclude systemic transduction. Cancer Gene Therapy. 1 December 2016. DOI: 10.1038/cgt.2016.50.

Impacto: 3.652. Cuartil: Q1

Rojas L.A., Condezo G.N., Olié R.M., Fajardo C.A., Arias-Badia M., San Martín C., Alemany R.. Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. Journal of Controlled Release. 10 September 2016. DOI: 10.1016/j.jconrel.2016.07.004.

Impacto: 7.786. Cuartil: Q1 (1er decil)

Villanueva E., Martí-Solano M., Fillat C.. Codon optimization of the adenoviral fiber negatively impacts structural protein expression and viral fitness. Scientific Reports. 9 June 2016. DOI: 10.1038/srep27546.

Impacto: 4.259. Cuartil: Q1

Vera B., Martínez-Vélez N., Xipell E., Acanda De La Rocha A., Patiño-García A., Castresana J., Gonzalez-Huarriz M., Cascallo M., Alemany R., Alonso M.. Correction: Characterization of the antiglioma effect of the oncolytic adenovirus VCN-01. PLoS ONE. 1 June 2016. DOI: 10.1371/journal.pone.0157619.

Impacto: 2.806. Cuartil: Q1

Martínez-Vélez N., Xipell E., Vera B., De La Rocha A.A., Zalacain M., Marrodan L., Gonzalez-Huarriz M., Toledo G., Cascallo M., Alemany R., Patiño A., Alonso M.M.. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. Clinical Cancer Research. 1 May 2016. DOI: 10.1158/1078-0432.CCR-15-1899.

Impacto: 9.619. Cuartil: Q1 (1er decil)

Alemany R.. Molecular Design of Oncolytic Adenoviruses. Adenoviral Vectors for Gene Therapy: Second Edition. 6 April 2016. DOI: 10.1016/B978-0-12-800276-6.00012-7.

Xipell E., Rivera-Molina Y., Gomez-Manzano C., Jiang H., Alonso M.M., Alemany R., Fueyo J.. Conditionally Replicative Adenoviruses-Clinical Trials. Adenoviral Vectors for Gene Therapy: Second Edition. 6 April 2016. DOI: 10.1016/B978-0-12-800276-6.00013-9.

Vera B., Martínez-Vélez N., Xipell E., De La Rocha A.A., Patiño-García A., Saez-Castresana J., Gonzalez-Huarriz M., Cascallo M., Alemany R., Alonso M.M.. Characterization of the antiglioma effect of the oncolytic adenovirus VCN-01. PLoS ONE. 1 January 2016. DOI: 10.1371/journal.pone.0147211.

Impacto: 2.806. Cuartil: Q1

Sanz-Pamplona R., Gil-Hoyos R., López-Doriga A., Alonso M.H., Aussó S., Molleví D.G., Santos C., Sanjuán X., Salazar R., Alemany R., Moreno V.. Mutanome and expression of immune response genes in microsatellite stable colon cancer. Oncotarget. 2016. DOI: 10.18632/oncotarget.7293.

Impacto: 5.168. Cuartil: Q1

Melen G.J., Franco-Luzón L., Ruano D., González-Murillo Á., Alfranca A., Casco F., Lassaletta Á., Alonso M., Madero L., Alemany R., García-Castro J., Ramírez M.. Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Letters. 2016. DOI: 10.1016/j.canlet.2015.11.036.

Impacto: 6.375. Cuartil: Q1

Alemany R., Izeta A., Garcia-Sancho J.. Highlights of 8th Biennial Congress of the Spanish Society of Gene and Cell Therapy. Human Gene Therapy. 1 January 2016. DOI: 10.1089/hum.2015.29015.ral.

Impacto: 4.187. Cuartil: Q1

Martínez-Bosch N., Guerrero P.E., Moreno M., José A., Iglesias M., Munné-Collado J., Anta H., Gibert J., Orozco C.A., Vinaixa J., Fillat C., Viñals F., Navarro P.. The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Oncotarget. 2016. DOI: 10.18632/oncotarget.10199.

Impacto: 5.168. Cuartil: Q1

Zaiss A.K., Foley E.M., Lawrence R., Schneider L.S., Hoveida H., Secrest P., Catapang A.B., Yamaguchi Y., Alemany R., Shayakhmetov D.M., Esko J.D., Herschman H.R.. Hepatocyte heparan sulfate is required for adeno-associated virus 2 but dispensable for adenovirus 5 liver transduction in vivo. Journal of Virology. 2016. DOI: 10.1128/JVI.01939-15.

Impacto: 4.663. Cuartil: Q1

Bofill-De Ros X., Santos M., Vila-Casadesús M., Villanueva E., Andreu N., Dierssen M., Fillat C.. Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges. BMC Genomics. November 06, 2015. DOI: 10.1186/s12864-015-2160-6.

Impacto: 3.867. Cuartil: Q1

Hoyos V., Del Bufalo F., Yagyu S., Ando M., Dotti G., Suzuki M., Bouchier-Hayes L., Alemany R., Brenner M.K.. Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Molecular Therapy. 3 September 2015. DOI: 10.1038/mt.2015.110.

Impacto: 6.938. Cuartil: Q1 (1er decil)

Maliandi M.V., Mato-Berciano A., Sobrevals L., Roué G., José A., Fillat C.. AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-KB mediated uPAR activation. Molecular Cancer. July 31, 2015. DOI: 10.1186/s12943-015-0413-2.

Impacto: 5.888. Cuartil: Q1

Rodríguez-García A., Svensson E., Gil-Hoyos R., Fajardo C.A., Rojas L.A., Arias-Badia M., Loskog A.S.I., Alemany R.. Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity. Gene Therapy. 3 July 2015. DOI: 10.1038/gt.2015.41.

Impacto: 3.242. Cuartil: Q2

Rodríguez-García A., Giménez-Alejandre M., Rojas J.J., Moreno R., Bazan-Peregrino M., Cascalló M., Ramon A.. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clinical Cancer Research. 15 March 2015. DOI: 10.1158/1078-0432.CCR-14-2213.

Impacto: 8.738. Cuartil: Q1 (1er decil)

Agirre M., Zarate J., Ojeda E., Puras G., Rojas L.A., Alemany R., Pedraz J.L.. Delivery of an adenovirus vector plasmid by ultrapure oligochitosan based polyplexes. International Journal of Pharmaceutics. 20 February 2015. DOI: 10.1016/j.ijpharm.2014.12.062.

Impacto: 3.994. Cuartil: Q1

Martinez-Quintanilla J., He D., Wakimoto H., Alemany R., Shah K.. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Molecular Therapy. 10 January 2015. DOI: 10.1038/mt.2014.204.

Impacto: 6.938. Cuartil: Q1 (1er decil)

Bofill-De Ros X., Villanueva E., Fillat C.. Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells. Oncotarget. 2015. DOI: 10.18632/oncotarget.3350.

Impacto: 5.008. Cuartil: Q1

José A., Rovira-Rigau M., Luna J., Giménez-Alejandre M., Vaquero E., García De La Torre B., Andreu D., Alemany R., Fillat C.. A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus. Journal of Controlled Release. 28 October 2014. DOI: 10.1016/j.jconrel.2014.07.008.

Impacto: 7.705. Cuartil: Q1 (1er decil)

Grau C., Arató K., Fernández-Fernández J.M., Valderrama A., Sindreu C., Fillat C., Ferrer I., de la Luna S., Altafaj X.. DYRK1A-mediated phosphorylation of GluN2A at ser<sup>1048</sup> regulates the surface expression and channel activity of GluN1/GluN2A receptors. Frontiers in Cellular Neuroscience. 17 October 2014. DOI: 10.3389/fncel.2014.00331.

Impacto: 4.289. Cuartil: Q1

Dong W., Van Ginkel J.W.H., Au K.Y., Alemany R., Meulenberg J.J.M., Van Beusechem V.W.. ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models. Human Gene Therapy. 1 October 2014. DOI: 10.1089/hum.2013.229.

Impacto: 3.755. Cuartil: Q1

Lopez-Gordo E., Podgorski I.I., Downes N., Alemany R.. Circumventing antivector immunity: Potential use of nonhuman adenoviral vectors. Human Gene Therapy. 1 April 2014. DOI: 10.1089/hum.2013.228.

Impacto: 3.755. Cuartil: Q1

Majhen D., Calderon H., Chandra N., Fajardo C.A., Rajan A., Alemany R., Custers J.. Adenovirus-based vaccines for fighting infectious diseases and cancer: Progress in the field. Human Gene Therapy. 1 April 2014. DOI: 10.1089/hum.2013.235.

Impacto: 3.755. Cuartil: Q1

Fillat C., Maliandi M.V., Mato-Berciano A., Alemany R.. Combining oncolytic virotherapy and cytotoxic therapies to fight cancer. Current Pharmaceutical Design. 1 March 2014. DOI: 10.2174/1381612820666140826152420.

Impacto: 3.452. Cuartil: Q1

Alemany R.. Oncolytic adenoviruses in cancer treatment. Biomedicines. 1 March 2014. DOI: 10.3390/biomedicines2010036.